Current evidence on tapering of tumor necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) is still hampered by heterogeneity in tapering regimens, selection and performance biases, and lack of data on optimized treatment dosing strategies especially in real-world clinical settings. This study aims to contribute to the ongoing investigation of disease-activity-guided tapering of TNFi in axSpA in the form of a prospective, randomized controlled trial.
1 Primary · 8 Secondary · Reporting Duration: Weeks 12, 24, 36, and 48
156 Total Participants · 2 Treatment Groups
Primary Treatment: Tapered doses of TNFi · No Placebo Group · Phase 4
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: